CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 244 enrolled
Drug / intervention
Xamiol® gel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01195831
NCT01195831Phase 3Completed

Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis.

LEO Pharma·interventional·Posted Sep 6, 2010·Updated Mar 12, 2025

In Brief

A Phase 3 clinical trial evaluating Xamiol® gel and Calcipotriol scalp solution for Scalp Psoriasis. Completed, enrolled 244 participants across 9 sites.

Detailed Summary

The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in patients with scalp psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScalp Psoriasis
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 6, 2010
Enrollment StartSep 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.8 years ago

Interventions

Xamiol® geldrug

Once daily application

Calcipotriol scalp solutiondrug

Twice daily application